Welcome to our dedicated page for Sensus Healthcare news (Ticker: SRTS), a resource for investors and traders seeking the latest updates and insights on Sensus Healthcare stock.
Sensus Healthcare, Inc. (Nasdaq: SRTS) is a medical device company that focuses on non-invasive and minimally-invasive treatments for oncological and non-oncological skin conditions using superficial radiotherapy (SRT and IG-SRT). The SRTS news page on Stock Titan aggregates company announcements, press releases and market updates so readers can follow how Sensus’ technology, reimbursement environment and commercial activities evolve over time.
Recent news highlights include recognition of Sensus Healthcare as a global pioneer in non-invasive treatments for skin cancer and keloids, updates on clinical evidence for its SRT systems, and developments in reimbursement policy. The company has reported that the Centers for Medicare & Medicaid Services established dedicated CPT codes specific to superficial radiotherapy for non-melanoma skin cancer, which Sensus describes as a pivotal moment for its platform and strategy. News items also cover growth in treatment volumes under its Fair Deal Agreement program and shipments of SRT systems to both U.S. and international customers.
Investors and healthcare professionals can use this news feed to track quarterly financial results, board and governance changes, conference participation, and recognition such as Sensus Healthcare’s inclusion in TIME’s America’s Growth Leaders of 2026 ranking. Clinical and scientific updates, including published studies on the use of SRT for keloids, provide additional context on how the company’s technology is being used in practice.
By reviewing the SRTS news stream regularly, readers can see how Sensus Healthcare communicates its progress in radiation oncology technology, reimbursement milestones, commercial expansion and clinical validation of its superficial radiotherapy solutions.
Sensus Healthcare (SRTS) reported first quarter 2022 revenues of $10.3 million, a 237% increase compared to the previous year. Net income surged to $16.1 million, or $0.97 per diluted share, thanks to a $12.8 million gain from asset sales. The company exited the quarter with $32.8 million in cash. Adjusted EBITDA improved to $16.9 million, up from a loss of $0.8 million year-on-year. Sensus affirms expectations for continued growth and profitability in Q2 and the full year.
Sensus Healthcare, Inc. (Nasdaq: SRTS) has announced a conference call scheduled for May 5, 2022, at 4:30 p.m. Eastern time to discuss its financial results for Q1 2022. The call will also include a business update covering recent and upcoming milestones. Investors can access the call via dial-in numbers or through a live webcast on the company's website. Sensus Healthcare specializes in non-invasive treatments for oncological and non-oncological conditions, utilizing low-energy X-ray technology for various medical applications.
Sensus Healthcare (Nasdaq: SRTS) recently announced successful treatments using its SRT-100 system, demonstrating its capability in veterinary oncology. A mata mata turtle at Denver Zoo was treated for squamous cell carcinoma, showing no signs of the lesion three months post-therapy. This follows earlier treatments on various animals at Colorado State University, expanding the application of SRT in veterinary medicine. The ongoing partnership with CSU aims to develop protocols and clinical data, highlighting potential growth in a new market segment.
Sensus Healthcare (Nasdaq: SRTS), a medical device company, is set to present at two investment conferences in March 2022. The 34th Annual ROTH Conference will be held from March 13-15, with a key ‘Fireside Chat’ on March 15 at 9:30 a.m. PT. Investors can access the chat and a pre-recorded presentation on the company's website. Additionally, Sensus will participate in the Maxim 2022 Virtual Growth Conference on March 28-29, joining an Aesthetic Device Industry Panel on March 28 from 1:00 p.m. to 2:30 p.m. ET.
Sensus Healthcare, Inc. (Nasdaq: SRTS) announced a share buyback program authorizing the purchase of up to $3,000,000 of its common stock. CEO Joe Sardano expressed optimism about the company's future and stated that the buyback is a strategy to enhance shareholder value. The program, which has no time limit, allows for purchases through various methods and is subject to management's discretion based on financial assessments and market conditions. Sensus specializes in non-invasive medical device treatments for cancer and other conditions.
Sensus Healthcare (Nasdaq: SRTS) has sold its Sculptura™ assets to Empyrean Medical Systems for $15 million in cash, completing the transaction on February 25, 2022. The sale allows Sensus to concentrate on its core dermatology business as it rebounds, utilizing proceeds to expand its dermatology product line, including new offerings like the TransDermal™ Infusion system and Laser Systems. This move aligns with Sensus's strategy to focus resources post-sale, which positions the company for growth in the dermatological segment.
Sensus Healthcare, Inc. (SRTS) reported a remarkable fourth quarter 2021 with revenues of $13.0 million, surging 156% year-over-year. Net income reached $5.3 million or $0.32 per diluted share, compared to $1.0 million or $0.06 in Q4 2020. The full-year revenue climbed to $27.0 million, a 182% increase from 2020. Positive momentum is expected to continue into 2022, bolstered by new product agreements and improved reimbursement rates. Management anticipates profitability for both the first quarter and full year of 2022.
Sensus Healthcare (Nasdaq: SRTS) announced key executive promotions as part of its strategy for long-term growth. Michael J. Sardano has been promoted to President, while Christopher Machuzak and Jeffrey Starling are now Vice Presidents of Sales for the West and East Coasts, respectively. This decision reflects the company's commitment to develop talent internally and enhance its leadership team. The announcement also included the retirement of Executive Vice President and Co-founder Steve Cohen. These changes aim to leverage leadership strengths and drive sustained sales growth, especially post-COVID-19.
Sensus Healthcare, Inc. (Nasdaq: SRTS) announced a conference call on February 10, 2022, at 4:30 p.m. ET to discuss Q4 and full-year 2021 financial results. The call will include a business update and a review of recent and upcoming milestones. Interested parties can join the call via dial-in or a live webcast accessible through the company's website. Sensus Healthcare specializes in non-invasive and minimally invasive treatments through advanced technologies like the Sculptura™ system and SRT-100™ for oncological and non-oncological conditions.
Sensus Healthcare (SRTS) announces participation in the H.C. Wainwright BioConnect Virtual Conference from January 10-13, 2022. CEO Joe Sardano will present a pre-recorded session available on-demand starting January 10 at 7:00 a.m. ET. Attendees can access the presentation via the company’s investor relations page. Additionally, Sensus management is open to virtual 1x1 meetings during the J.P. Morgan Healthcare Conference from January 10-14. Interested parties can schedule meetings through email.